Professor Emma Thomson

Professor in Infectious Diseases (Virology)

telephone: 01413302928
email: Emma.Thomson@glasgow.ac.uk

MRC Centre for Virus Research, Sir Michael Stoker building, 464 Bearsden Road, Glasgow, G61 1qh

Research interests

Emerging viral infections are an ever-present threat to human health. The risk of transmission of viruses to previously unexposed populations has increased as a result of increased global travel, global warming and changes in our ecosystem and human behaviour. I have worked on a number of emerging viral infections including AAV2, mpox, SARS-CoV-2, hepatitis C and E, Ebola virus, emerging rhabdovirusesand Crimean-Congo haemorrhagic fever virus (CCHFV). My laboratory uses next generation sequencing to detect new and emerging viruses in the UK and in Uganda in partnership with researchers at the Uganda Virus Research Institute (UVRI). We are engaged in improving diagnostic capacity so that undiagnosed new or emerging infections may be detected at source more rapidly in the future, allowing for early control interventions. We aim to investigate drivers of virus evolution using B and T cell functional assays including neutralization, ELISpot and flow cytometry.

I work as an infectious diseases and general (internal) medicine consultant with specialist interests in returning travellers with fever, early hepatitis C infection, HCV drug resistance and HIV co-infection at the Queen Elizabeth University Hospital in Glasgow and have experience looking after patients with a wide range of infectious diseases. I am chair of the British HIV Association Hepatitis Sub-committee and work as an external consultant for the World Health Organisation.

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003

Number of items: 120.

2024

Namuwulya, P. et al. (2024) Viruses associated with measles-like illnesses in Uganda. Journal of Infection, (doi: 10.1016/j.jinf.2024.106148) (PMID:38588959) (In Press)

2023

Michael, B. D. et al. (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14, 8487. (doi: 10.1038/s41467-023-42320-4) (PMID:38135686) (PMCID:PMC10746705)

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Pascall, D. J. et al. (2023) Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. Journal of Infection, 87(2), pp. 128-135. (doi: 10.1016/j.jinf.2023.05.019) (PMID:37270070) (PMCID:PMC10234362)

Liu, X. et al. (2023) Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Journal of Infection, 87(1), pp. 18-26. (doi: 10.1016/j.jinf.2023.04.012) (PMID:37085049) (PMCID:PMC10116128)

Shepherd, J. G. , Davis, C. , Streicker, D. G. and Thomson, E. C. (2023) Emerging rhabdoviruses and human infection. Biology, 12(6), 878. (doi: 10.3390/biology12060878) (PMID:37372162) (PMCID:PMC10294888)

Ho, A. et al. (2023) Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature, 617(7961), pp. 555-563. (doi: 10.1038/s41586-023-05948-2) (PMID:36996873)

Morfopoulou, S. et al. (2023) Genomic investigations of unexplained acute hepatitis in children. Nature, 617(7961), pp. 564-573. (doi: 10.1038/s41586-023-06003-w) (PMID:36996872)

Pascall, D. J. et al. (2023) The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: a genomics-based retrospective cohort analysis. PLoS ONE, 18(4), e0284187. (doi: 10.1371/journal.pone.0284187) (PMID:37053201) (PMCID:PMC10101505)

Heath, P. T. et al. (2023) Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clinical Infectious Diseases, 76(3), pp. 298-407. (doi: 10.1093/cid/ciac803) (PMID:36210481) (PMCID:PMC9619635)

Cox, M. et al. (2023) SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nature Reviews Microbiology, 21(2), pp. 112-124. (doi: 10.1038/s41579-022-00809-7) (PMID:36307535) (PMCID:PMC9616429)

Atim, S. A. et al. (2023) Prevalence of Crimean-Congo haemorrhagic fever in livestock following a confirmed human case in Lyantonde district, Uganda. Parasites and Vectors, 16, 7. (doi: 10.1186/s13071-022-05588-x) (PMID:36611216) (PMCID:PMC9824997)

Manali, M. et al. (2023) SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. Journal of Infectious Diseases, 227(1), pp. 40-49. (doi: 10.1093/infdis/jiac332) (PMID:35920058) (PMCID:PMC9384671)

Adesina, A. S. et al. (2023) Circulation of Lassa virus across the endemic Edo-Ondo axis, Nigeria, with cross-species transmission between multimammate mice. Emerging Microbes and Infections, 12(1), 2219350. (doi: 10.1080/22221751.2023.2219350) (PMID:37288752) (PMCID:PMC10251791)

Nickbakhsh, S. , McWilliam Leitch, E. C., Smith, S., Davis, C. , Hutchinson, S., Irving, W. L., McLauchlan, J. and Thomson, E. C. (2023) Geographical variation in Hepatitis C-related severe liver disease and patient risk factors: a multicentre cross-sectional study. Epidemiology and Infection, 151, e59. (doi: 10.1017/S0950268823000377) (PMID:36915219) (PMCID:PMC10126891)

2022

Atim, S. A. et al. (2022) Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda. Journal of Infection, 85(6), pp. 693-701. (doi: 10.1016/j.jinf.2022.09.007) (PMID:36108783) (PMCID:PMC9731351)

Aranday-Cortes, E. et al. (2022) Real-world outcomes of direct-acting antiviral treatment and retreatment in United Kingdom–based patients infected with hepatitis C virus genotypes/subtypes endemic in Africa. Journal of Infectious Diseases, 226(6), pp. 995-1004. (doi: 10.1093/infdis/jiab110) (PMID:33668068) (PMCID:PMC9492310)

Stirrup, O. et al. (2022) Effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control for hospital-onset COVID-19 infection: multicenter, prospective study. eLife, 11, e78427. (doi: 10.7554/elife.78427) (PMID:36098502) (PMCID:PMC9596156)

Munro, A. P. S. et al. (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, 22(8), pp. 1131-1141. (doi: 10.1016/S1473-3099(22)00271-7) (PMID:35550261) (PMCID:PMC9084623)

Shah, R. et al. (2022) Characterisation of a hepatitis C virus subtype 2a cluster in Scottish PWID with a suboptimal response to glecaprevir/pibrentasvir treatment. Viruses, 14(8), 1678. (doi: 10.3390/v14081678) (PMID:36016300) (PMCID:PMC9416734)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Nickbakhsh, S. et al. (2022) Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. Scientific Reports, 12, 11735. (doi: 10.1038/s41598-022-15661-1) (PMID:35853960) (PMCID:PMC9296497)

Hufsky, F. et al. (2022) Women in the European Virus Bioinformatics Center. Viruses, 14(7), 1522. (doi: 10.3390/v14071522) (PMID:35891501) (PMCID:PMC9319252)

Liu, X. et al. (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. Journal of Infection, 84(6), pp. 795-813. (doi: 10.1016/j.jinf.2022.04.018) (PMID:35405168) (PMCID:PMC8993491)

McGill, F. et al. (2022) Viral capture sequencing detects unexpected viruses in the cerebrospinal fluid of adults with meningitis. Journal of Infection, 84(4), pp. 499-510. (doi: 10.1016/j.jinf.2021.12.042) (PMID:34990710)

Stockdale, A. J. et al. (2022) A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission. Journal of Viral Hepatitis, 29(4), pp. 252-262. (doi: 10.1111/jvh.13646) (PMID:35075742) (PMCID:PMC9305194)

Aggarwal, D. et al. (2022) Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications, 13, 1012. (doi: 10.1038/s41467-022-28371-z) (PMID:35197443) (PMCID:PMC8866425)

Aggarwal, D. et al. (2022) Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications, 13, 751. (doi: 10.1038/s41467-021-27942-w) (PMID:35136068) (PMCID:PMC8826310)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

Twohig, K. A. et al. (2022) Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, 22(1), pp. 35-42. (doi: 10.1016/S1473-3099(21)00475-8) (PMID:34461056) (PMCID:PMC8397301)

2021

Munro, A. P.S. et al. (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 398(10318), pp. 2258-2276. (doi: 10.1016/S0140-6736(21)02717-3) (PMID:34863358) (PMCID:PMC8639161)

Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)

Vöhringer, H. S. et al. (2021) Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 600(7889), pp. 506-511. (doi: 10.1038/s41586-021-04069-y) (PMID:34649268) (PMCID:PMC8674138)

Boshier, F. A.T. et al. (2021) The Alpha variant was not associated with excess nosocomial SARS-CoV-2 infection in a multi-centre UK hospital study. Journal of Infection, 83(6), pp. 693-700. (doi: 10.1016/j.jinf.2021.09.022) (PMID:34610391) (PMCID:PMC8487101)

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Wood, R. et al. (2021) Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Archives of Disease in Childhood, 106(12), pp. 1212-1217. (doi: 10.1136/archdischild-2021-321604) (PMID:33737319) (PMCID:PMC7985971)

Witkowska McConnell, W. et al. (2021) Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. Nature Communications, 12, 6994. (doi: 10.1038/s41467-021-27076-z) (PMID:34848705) (PMCID:PMC8632961)

Swanson, P. A. et al. (2021) AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire. Science Translational Medicine, 13(620), eabj7211. (doi: 10.1126/scitranslmed.abj7211) (PMID:34591596)

Smith, D. A. et al. (2021) Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nature Communications, 12, 6105. (doi: 10.1038/s41467-021-25649-6) (PMID:34671027) (PMCID:PMC8528821)

Mayanja, M. N., Mwiine, F. N., Lutwama, J. J., Ssekagiri, A., Egesa, M., Thomson, E. C. and Kohl, A. (2021) Mosquito-borne arboviruses in Uganda: history, transmission and burden. Journal of General Virology, 102(10), 001680. (doi: 10.1099/jgv.0.001680) (PMID:34609940)

Shah, R. et al. (2021) Hepatitis C virus in sub-Saharan Africa: a long road to elimination. Lancet Gastroenterology and Hepatology, 6(9), pp. 693-694. (doi: 10.1016/S2468-1253(21)00224-7) (PMID:34391525)

Smith, D. A. et al. (2021) Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. Journal of Viral Hepatitis, 28(9), pp. 1256-1264. (doi: 10.1111/jvh.13549) (PMID:34003556)

Szemiel, A. M. et al. (2021) In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathogens, 17(9), e1009929. (doi: 10.1371/journal.ppat.1009929) (PMID:34534263) (PMCID:PMC8496873)

Collier, D. A. et al. (2021) Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 596(7872), pp. 417-422. (doi: 10.1038/s41586-021-03739-1) (PMID:34192737) (PMCID:PMC8373615)

Russell, C. D. et al. (2021) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, 2(8), e354-e365. (doi: 10.1016/S2666-5247(21)00090-2) (PMID:34100002) (PMCID:PMC8172149)

Thomson, E. , Shah, R., Ahovegbe, L., Niebel, M. and Shepherd, J. (2021) Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. Journal of Hepatology, 75(2), pp. 462-473. (doi: 10.1016/j.jhep.2021.04.045) (PMID:33974951) (PMCID:PMC8310923)

Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)

Harvey, W. T. et al. (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology, 19(7), pp. 409-424. (doi: 10.1038/s41579-021-00573-0) (PMID:34075212) (PMCID:PMC8167834)

Li, K. K. et al. (2021) Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - a high risk community-hospital interface. Journal of Infection, 83(1), pp. 96-103. (doi: 10.1016/j.jinf.2021.04.020) (PMID:33895226) (PMCID:PMC8061788)

Stirrup, O. et al. (2021) Rapid feedback on hospital onset SARS-CoV-2 infections combining epidemiological and sequencing data. eLife, 10, e65828. (doi: 10.7554/elife.65828) (PMID:34184637) (PMCID:PMC8285103)

Davis, C. A. et al. (2021) Hepatitis E virus: whole genome sequencing as a new tool for understanding HEV epidemiology and phenotypes. Journal of Clinical Virology, 139, 104738. (doi: 10.1016/j.jcv.2021.104738) (PMID:33933822)

Mayanja, M. N., Mwiine, F., Lutwama, J. J., Sssekagiri, A., Egesa, M., Thomson, E. C. and Kohl, A. (2021) Mosquito-borne arboviruses in Uganda: history, transmission and burden. Journal of General Virology, 102(6), 001615. (doi: 10.1099/jgv.0.001615) (PMID:34166178)

Graham, M. S. et al. (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health, 6(5), e335-e345. (doi: 10.1016/S2468-2667(21)00055-4)

Volz, E. et al. (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature, 593(7858), pp. 266-269. (doi: 10.1038/s41586-021-03470-x) (PMID:33767447)

Lythgoe, K. A. et al. (2021) SARS-CoV-2 within-host diversity and transmission. Science, 372(6539), eabg0821. (doi: 10.1126/science.abg0821) (PMID:33688063) (PMCID:PMC8128293)

Emary, K. R. W. et al. (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 397(10282), pp. 1351-1362. (doi: 10.1016/S0140-6736(21)00628-0) (PMID:33798499) (PMCID:PMC8009612)

Voysey, M. et al. (2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, 397(10277), pp. 881-891. (doi: 10.1016/S0140-6736(21)00432-3) (PMID:33617777) (PMCID:PMC7894131)

Thomson, E. C. et al. (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e20. (doi: 10.1016/j.cell.2021.01.037) (PMID:33621484) (PMCID:PMC7843029)

Rihn, S. J. et al. (2021) A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 19(2), e3001091. (doi: 10.1371/journal.pbio.3001091) (PMID:33630831) (PMCID:PMC7906417)

Voysey, M. et al. (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), pp. 99-111. (doi: 10.1016/S0140-6736(20)32661-1) (PMID:33306989) (PMCID:PMC7723445)

Volz, E. et al. (2021) Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. Cell, 184(1), 64-75.e11. (doi: 10.1016/j.cell.2020.11.020) (PMID:33275900) (PMCID:PMC7674007)

Bangura, U. et al. (2021) Lassa virus circulation in small mammal populations in Bo District, Sierra Leone. Biology, 10(1), 28. (doi: 10.3390/biology10010028) (PMID:33466234) (PMCID:PMC7824740)

Da Silva Filipe, A. et al. (2021) Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland. Nature Microbiology, 6(1), pp. 112-122. (doi: 10.1038/s41564-020-00838-z) (PMID:33349681)

Parker, M. D. et al. (2021) Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. Genome Research, 31, pp. 645-658. (doi: 10.1101/gr.268110.120) (PMID:33722935) (PMCID:PMC8015849)

Stirrup, O. et al. (2021) SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. BMJ Open Respiratory Research, 8, e001029. (doi: 10.1136/bmjresp-2021-001029) (PMID:34544733) (PMCID:PMC8453594)

2020

Gilbert, M. et al. (2020) Distemper, extinction and vaccination of the Amur tiger. Proceedings of the National Academy of Sciences of the United States of America, 117(50), pp. 31954-31962. (doi: 10.1073/pnas.2000153117) (PMID:33229566) (PMCID:PMC7749280)

Davis, C. et al. (2020) Postexposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the United Kingdom: an operational, safety, and immunogenicity report. Clinical Infectious Diseases, 71(11), pp. 2872-2879. (doi: 10.1093/cid/ciz1165) (PMID:31784751) (PMCID:PMC7778350)

Sabir, S. R., Thomson, E. C. , Guzik, T. J., D’Acquisto, F. and Maffia, P. (2020) COVID-19: the new immune challenge. Frontiers for Young Minds, 8, 582971. (doi: 10.3389/frym.2020.582971)

Guzik, T. J. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 116(10), pp. 1666-1687. (doi: 10.1093/cvr/cvaa106) (PMID:32352535) (PMCID:PMC7197627)

Bradshaw, D. et al. (2020) Transmission of hepatitis C virus in HIV‐positive and PrEP‐using MSM in England. Journal of Viral Hepatitis, 27(7), pp. 721-730. (doi: 10.1111/jvh.13286) (PMID:32115809)

Mayanja, M. N., Mwiine, F. N., Kohl, A. , Thomson, E. C. and Lutwama, J. J. (2020) An update on the mosquito species composition and diversity in western and North Western Uganda. Journal of Entomology and Zoology Studies, 8(2), pp. 1074-1086.

Childs, K., Cannon, M., Davis, C. , Thomson, E. C. , Dusheiko, G. and Agarwal, K. (2020) Reply to: “Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action”. Journal of Hepatology, 72(3), pp. 585-586. (doi: 10.1016/j.jhep.2019.11.010) (PMID:31870568)

Fawsitt, C. G. et al. (2020) Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chronic hepatitis C virus. Value in Health, 23(2), pp. 180-190. (doi: 10.1016/j.jval.2019.08.012) (PMID:32113623) (PMCID:PMC7057278)

2019

Bradshaw, D. et al. (2019) Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. Journal of Infection, 79(6), pp. 503-512. (doi: 10.1016/j.jinf.2019.10.007) (PMID:31629015)

Childs, K. et al. (2019) Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C. Journal of Hepatology, 71(6), pp. 1099-1105. (doi: 10.1016/j.jhep.2019.07.025) (PMID:31400349)

Baylis, S. A. et al. (2019) Development of a World Health Organization International Reference Panel for different genotypes of hepatitis E virus for nucleic acid amplification testing. Journal of Clinical Virology, 119, pp. 60-67. (doi: 10.1016/j.jcv.2019.05.006) (PMID:31431408)

Jerome, H. et al. (2019) Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. Journal of Infection, 79(4), pp. 383-388. (doi: 10.1016/j.jinf.2019.08.003) (PMID:31398374) (PMCID:PMC6859916)

Ansari, M. A. et al. (2019) Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. eLife, 8, e42463. (doi: 10.7554/eLife.42463) (PMID:31478835) (PMCID:PMC6721795)

Ankcorn, M. et al. (2019) Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology, 71(2), pp. 434-438. (doi: 10.1016/j.jhep.2019.04.008) (PMID:31075322)

Fawsitt, C. G. et al. (2019) A cost-effectiveness analysis of shortened direct-acting antiviral treatment in genotype 1 noncirrhotic treatment-naive patients with chronic hepatitis C virus. Value in Health, 22(6), pp. 693-703. (doi: 10.1016/j.jval.2018.12.011) (PMID:31198187) (PMCID:PMC6588649)

Singer, J. B. et al. (2019) Interpreting viral deep sequencing data with GLUE. Viruses, 11(4), 323. (doi: 10.3390/v11040323) (PMID:30987147) (PMCID:PMC6520954)

Davis, C. et al. (2019) New highly diverse hepatitis C strains detected in sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments. Hepatology, 69(4), pp. 1426-1441. (doi: 10.1002/hep.30342) (PMID:30387174) (PMCID:PMC6492010)

2018

Singer, J. B., Thomson, E. C. , McLauchlan, J. , Hughes, J. and Gifford, R. J. (2018) GLUE: a flexible software system for virus sequence data. BMC Bioinformatics, 19, 532. (doi: 10.1186/s12859-018-2459-9) (PMID:30563445) (PMCID:PMC6299651)

Mercuri, L., Thomson, E. C. , Hughes, J. and Karayiannis, P. (2018) Quasispecies changes with distinctive point mutations in the Hepatitis C virus internal ribosome entry site (IRES) derived from PBMCs and plasma. Advances in Virology, 2018, 4835252. (doi: 10.1155/2018/4835252) (PMID:30581467) (PMCID:PMC6276526)

Thomson, E. (2018) HIV and HCV co-infection - Does it matter in the era of direct-acting antiviral therapies? Microbiology Today, 45(4), pp. 176-179.

da Silva Filipe, A. et al. (2018) Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". Journal of Hepatology, 68(4), pp. 864-866. (doi: 10.1016/j.jhep.2017.11.044) (PMID:29339112)

2017

da Silva Filipe, A. et al. (2017) Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries. Journal of Hepatology, 67(6), pp. 1348-1350. (doi: 10.1016/j.jhep.2017.06.035) (PMID:28789880)

Niebel, M. , Singer, J. B., Nickbakhsh, S. , Gifford, R. J. and Thomson, E. C. (2017) Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination? Lancet Gastroenterology and Hepatology, 2(10), pp. 700-701. (doi: 10.1016/S2468-1253(17)30257-1) (PMID:28895545)

Shepherd, S. J., Black, H., Thomson, E. C. and Gunson, R. N. (2017) HIV positive patient with GBS-like syndrome. JMM Case Reports, 4(8), e005107. (doi: 10.1099/jmmcr.0.005107) (PMID:29026634) (PMCID:PMC5610709)

Ansari, M. A. et al. (2017) Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nature Genetics, 49(5), pp. 666-673. (doi: 10.1038/ng.3835) (PMID:28394351)

2016

Thomson, E. et al. (2016) Comparison of next-generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. Journal of Clinical Microbiology, 54(10), pp. 2470-2484. (doi: 10.1128/JCM.00330-16) (PMID:27385709) (PMCID:PMC5035407)

Jacobs, M. et al. (2016) Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, 388(10043), pp. 498-503. (doi: 10.1016/S0140-6736(16)30386-5) (PMID:27209148) (PMCID:PMC4967715)

Martin, N. K. et al. (2016) Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights. Clinical Infectious Diseases, 62(9), pp. 1072-1080. (doi: 10.1093/cid/ciw075) (PMID:26908813) (PMCID:PMC4826456)

Swann, R. E. , Cowton, V. M., Robinson, M. W., Cole, S. J., Barclay, S. T., Mills, P. R., Thomson, E. C. , McLauchlan, J. and Patel, A. (2016) Broad anti-hepatitis C virus (HCV) antibody responses are associated with improved clinical disease parameters in chronic HCV infection. Journal of Virology, 90(9), pp. 4530-4543. (doi: 10.1128/JVI.02669-15) (PMID:26912610) (PMCID:PMC4836347)

Robinson, M. W., Hughes, J. , Wilkie, G. S., Swann, R. , Barclay, S. T., Mills, P. R., Patel, A. H. , Thomson, E. C. and McLauchlan, J. (2016) Tracking TCRß sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Frontiers in Immunology, 7, 131. (doi: 10.3389/fimmu.2016.00131) (PMID:27092143) (PMCID:PMC4820669)

Padam, P., Clark, S., Irving, W., Gellissen, R., Thomson, E. , Main, J. and Cooke, G.S. (2016) Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease. Journal of Viral Hepatitis, 23(2), pp. 123-129. (doi: 10.1111/jvh.12484) (PMID:26511293) (PMCID:PMC4924594)

Martin, F., Lee, J., Thomson, E. , Tarrant, N., Hale, A. and Lacey, C. J. (2016) Two cases of possible transmitted drug resistant HIV virus: likely HIV superinfection and unmasking of pre-existing resistance. International Journal of STD and AIDS, 27(1), pp. 66-69. (doi: 10.1177/0956462415571671) (PMID:25663247) (PMCID:PMC4674743)

2015

Jerome, H., Vattipally, S. B. and Thomson, E. C. (2015) Can we identify potential viral zoonoses before they cross the species barrier? Microbiology Today, 42(4), pp. 150-153.

Gaunt, E., Harvala, H., Osterback, R., Sreenu, V. B. , Thomson, E. , Waris, M. and Simmonds, P. (2015) Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. Journal of General Virology, 96(5), pp. 1067-1079. (doi: 10.1099/vir.0.000062) (PMID:25614593) (PMCID:PMC4631059)

Abdelrahman, T., Hughes, J. , Main, J., McLauchlan, J. , Thursz, M. and Thomson, E. (2015) Reply. Hepatology, 61(4), p. 1438. (doi: 10.1002/hep.27393) (PMID:25147121) (PMCID:PMC4407921)

Ardelrahman, T., Hughes, J. , Main, J., McLauchlan, J. , Thursz, M. and Thomson, E. (2015) Waiting time and transplantation for hepatocellular cancer: a balance between tempus fugit and carpe diem. Hepatology, 61(4), pp. 1438-1439. (doi: 10.1002/hep.27434)

Shepherd, S. J., Abdelrahman, T., MacLean, A. R., Thomson, E. C. , Aitken, C. and Gunson, R. N. (2015) Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. Journal of Clinical Virology, 65, pp. 50-53. (doi: 10.1016/j.jcv.2015.02.005) (PMID:25766988) (PMCID:PMC4728298)

Abdelrahman, T., Hughes, J. , Main, J., McLauchlan, J. , Thursz, M. and Thomson, E. (2015) Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment. Hepatology, 61(1), pp. 88-97. (doi: 10.1002/hep.27192) (PMID:24797101) (PMCID:PMC4303934)

2014

McNaughton, A.L., Thomson, E.C. , Templeton, K., Gunson, R.N. and McWilliam Leitch, E.C. (2014) Mixed genotype hepatitis C infections and implications for treatment. Hepatology, 59(3), p. 1209. (doi: 10.1002/hep.26544) (PMID:23744801) (PMCID:PMC4296219)

2013

Leggewie, M., Sreenu, V. B. , Abdelrahman, T., Leitch, E. C., Wilkie, G., Klymenko, T., Muir, D., Thursz, M., Main, J. and Thomson, E.C. (2013) Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS, 27(15), pp. 2485-2488. (doi: 10.1097/QAD.0b013e328363b1f9) (PMID:23770494)

2011

Thomson, E.C. , Smith, J.A. and Klenerman, P. (2011) The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. Journal of General Virology, 92(10), pp. 2227-2236. (doi: 10.1099/vir.0.033910-0)

Thomson, E.C. , Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J., Smith, J., McClure, M.O. and Karayiannis, P. (2011) Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut, 60(6), pp. 837-845. (doi: 10.1136/gut.2010.217166)

2010

Huang, K.-H.G. et al. (2010) B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nature Communications, 1, 102. (doi: 10.1038/ncomms1100) (PMID:20981030) (PMCID:PMC2963804)

Smith, J.A., Aberle, J.H., Fleming, V.M., Ferenci, P., Thomson, E.C. , Karayiannis, P., McLean, A.R., Holzmann, H. and Klenerman, P. (2010) Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Journal of Infectious Diseases, 202(12), pp. 1770-1779. (doi: 10.1086/657317)

Winston, A. et al. (2010) Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? Journal of Viral Hepatitis, 17(6), pp. 419-426. (doi: 10.1111/j.1365-2893.2009.01198.x)

2009

Thomson, E.C. , Nastouli, E., Main, J., Karayiannis, P., Eliahoo, J., Muir, D. and McClure, M.O. (2009) Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS, 23(1), pp. 89-93. (doi: 10.1097/QAD.0b013e32831940a3)

Nastouli, E., Thomson, E.C. , Karayiannis, P., Main, J., McClure, M. and Muir, D. (2009) Diagnosing acute hepatitis C in HIV-infected patients: nucleic acid testing compared with antibody and antigen-antibody detecting methods. Journal of Clinical Virology, 44(1), pp. 78-80. (doi: 10.1016/j.jcv.2008.09.008)

2008

Fox, J., Nastouli, E., Thomson, E.C. , Muir, D., McClure, M., Weber, J. and Fidler, S. (2008) Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS, 22(5), pp. 666-668. (doi: 10.1097/QAD.0b013e3282f5f4cf)

Thomson, E.C. and Main, J. (2008) Epidemiology of hepatitis C virus infection in HIV-infected individuals. Journal of Viral Hepatitis, 15(11), pp. 773-781. (doi: 10.1111/j.1365-2893.2008.00981.x)

2007

Garvey, L., Thomson, E.C. , Main, J. and Winston, A. (2007) Response to "Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment". JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46(5), pp. 656-657. (doi: 10.1097/QAI.0b013e318157b0c8)

Garvey, L.J., Thomson, E.C. , Lloyd, J., Cooke, G.S., Goldin, R.D. and Main, J. (2007) Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS, 21(11), pp. 1494-1495. (doi: 10.1097/QAD.0b013e3281e7ed64)

2006

Bloom, C., Thomson, E.C. and Main, J. (2006) An elderly lady with sudden blindness and a sore foot. Journal of Infection, 52(2), e53-e54. (doi: 10.1016/j.jinf.2005.05.002)

Garvey, L., Thomson, E.C. and Taylor, G.P. (2006) Progressive multifocal leukoencephalopathy: prolonged survival in patients treated with protease inhibitors and cidofovir: a case series. AIDS, 20(5), pp. 791-793. (doi: 10.1097/01.aids.0000216390.83351.87)

2004

Thomson, E.C. and Main, J. (2004) Advances in hepatitis B and C. Current Opinion in Infectious Diseases, 17(5), pp. 449-459.

2003

Thomson, E.C. and Lynn, W.A. (2003) Septic thrombophlebitis with multiple pulmonary abscesses. Lancet Infectious Diseases, 3(2), p. 86. (doi: 10.1016/S1473-3099(03)00516-4)

This list was generated on Thu Apr 18 09:03:55 2024 BST.

Jump to: Articles

Number of items: 120.

Articles

Namuwulya, P. et al. (2024) Viruses associated with measles-like illnesses in Uganda. Journal of Infection, (doi: 10.1016/j.jinf.2024.106148) (PMID:38588959) (In Press)

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Ho, A. et al. (2023) Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature, 617(7961), pp. 555-563. (doi: 10.1038/s41586-023-05948-2) (PMID:36996873)

Morfopoulou, S. et al. (2023) Genomic investigations of unexplained acute hepatitis in children. Nature, 617(7961), pp. 564-573. (doi: 10.1038/s41586-023-06003-w) (PMID:36996872)

Hufsky, F. et al. (2022) Women in the European Virus Bioinformatics Center. Viruses, 14(7), 1522. (doi: 10.3390/v14071522) (PMID:35891501) (PMCID:PMC9319252)

Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)

Vöhringer, H. S. et al. (2021) Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 600(7889), pp. 506-511. (doi: 10.1038/s41586-021-04069-y) (PMID:34649268) (PMCID:PMC8674138)

Volz, E. et al. (2021) Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature, 593(7858), pp. 266-269. (doi: 10.1038/s41586-021-03470-x) (PMID:33767447)

Lythgoe, K. A. et al. (2021) SARS-CoV-2 within-host diversity and transmission. Science, 372(6539), eabg0821. (doi: 10.1126/science.abg0821) (PMID:33688063) (PMCID:PMC8128293)

Bangura, U. et al. (2021) Lassa virus circulation in small mammal populations in Bo District, Sierra Leone. Biology, 10(1), 28. (doi: 10.3390/biology10010028) (PMID:33466234) (PMCID:PMC7824740)

Parker, M. D. et al. (2021) Subgenomic RNA identification in SARS-CoV-2 genomic sequencing data. Genome Research, 31, pp. 645-658. (doi: 10.1101/gr.268110.120) (PMID:33722935) (PMCID:PMC8015849)

Sabir, S. R., Thomson, E. C. , Guzik, T. J., D’Acquisto, F. and Maffia, P. (2020) COVID-19: the new immune challenge. Frontiers for Young Minds, 8, 582971. (doi: 10.3389/frym.2020.582971)

Ansari, M. A. et al. (2019) Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. eLife, 8, e42463. (doi: 10.7554/eLife.42463) (PMID:31478835) (PMCID:PMC6721795)

Ankcorn, M. et al. (2019) Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology, 71(2), pp. 434-438. (doi: 10.1016/j.jhep.2019.04.008) (PMID:31075322)

Singer, J. B. et al. (2019) Interpreting viral deep sequencing data with GLUE. Viruses, 11(4), 323. (doi: 10.3390/v11040323) (PMID:30987147) (PMCID:PMC6520954)

Thomson, E. (2018) HIV and HCV co-infection - Does it matter in the era of direct-acting antiviral therapies? Microbiology Today, 45(4), pp. 176-179.

Jerome, H., Vattipally, S. B. and Thomson, E. C. (2015) Can we identify potential viral zoonoses before they cross the species barrier? Microbiology Today, 42(4), pp. 150-153.

Abdelrahman, T., Hughes, J. , Main, J., McLauchlan, J. , Thursz, M. and Thomson, E. (2015) Reply. Hepatology, 61(4), p. 1438. (doi: 10.1002/hep.27393) (PMID:25147121) (PMCID:PMC4407921)

Thomson, E.C. and Main, J. (2008) Epidemiology of hepatitis C virus infection in HIV-infected individuals. Journal of Viral Hepatitis, 15(11), pp. 773-781. (doi: 10.1111/j.1365-2893.2008.00981.x)

Bloom, C., Thomson, E.C. and Main, J. (2006) An elderly lady with sudden blindness and a sore foot. Journal of Infection, 52(2), e53-e54. (doi: 10.1016/j.jinf.2005.05.002)

Thomson, E.C. and Main, J. (2004) Advances in hepatitis B and C. Current Opinion in Infectious Diseases, 17(5), pp. 449-459.

Thomson, E.C. and Lynn, W.A. (2003) Septic thrombophlebitis with multiple pulmonary abscesses. Lancet Infectious Diseases, 3(2), p. 86. (doi: 10.1016/S1473-3099(03)00516-4)

This list was generated on Thu Apr 18 09:03:55 2024 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

Enhancing Crimean-Congo Hemorrhagic Fever Virus (CCHFV) epitope detection in Uganda by high-throughput serology
Scottish Funding Council
2023 - 2024
CVR Preparedness compute capacity
Medical Research Council
2023 - 2024
MonkeyPox - Rapid Response
Biotechnology and Biological Sciences Research Council
2022 - 2023
ISARIC Hepatitis
Medical Research Council
2022 - 2024
Identification of viruses causing undiagnosed febrile illness in returning travellers to the UK using enhanced NGS-based metagenomic methods
UK Research and Innovation
2022 - 2023
ISARIC4C Clinical Characterisation Protocol (CCP) activation for acute severe hepatitis in children of unknown cause
Medical Research Council
2022 - 2023
Using virus genomic data to inform the COVID-19 response: Risks of VOC introductions and spread
Public Health Scotland
2022 - 2022
Evaluation of Variants Affecting Deployed COVID-19 Vaccines
Health Data Research UK
2021 - 2022
Priming elimination of hepatitis C in Sub-Saharan Africa; Development of a treatment and bioresource network
Academy of Medical Sciences
2021 - 2022
Genotype to Phenotype Consortium
UK Research and Innovation
2021 - 2022
COVID
Medical Research Council
2021 - 2022
COG-HOCI sub-project - COVID-19
UK Research and Innovation
2020 - 2021
Strengthening viral haemorrhagic fever preparedness in Uganda by serosurveillance of healthcare workers
National Institute for Health Research
2020 - 2021
UKPHRST - Strengthening viral haemorrhagic fever preparedness in Uganda by serosurveillance of healthcare workers
National Institute for Health Research
2020 - 2021
UK COVID-19 genomic surveillance consortium - MRC CVR
UK Research and Innovation
2020 - 2021
UK COVID-19 genomic surveillance consortium ¿ MRC CVR
UK Research and Innovation
2020 - 2022
ISARIC - Coronavirus Clinical Characterisation Consortium
Medical Research Council
2020 - 2021
Using new molecular sequencing techniques to establish aetiology in cases of adult onset meningitis
Wellcome Trust
2018 - 2020
SFC-GCRF: A framework for the diagnosis and control of viral diseases in West Africa; from surveillance to health economics
Scottish Funding Council
2016 - 2017
Quinquennial Core Funds
Medical Research Council
2016 - 2021
Is the Ugandan Population Vulnerable to a Zika Virus Epidemic?
Medical Research Council
2016 - 2017
T-cell mediated evolution of hepatitis C virus during acute infection
Wellcome Trust
2014 - 2018
Stratified medicine to Optimise the Treatment with Hepatitis C Virus Infection (STOP-HCV) *** Original Agreement Budgets and Costs***
Medical Research Council
2013 - 2018
Relapse after treatment for acute HCV infection in HIV-positive men; viral recrudescence or reinfection?
British HIV Association
2011 - 2013

Supervision

Kugler, Marina
Wellcome Trust - IIB programme

Research datasets

Jump to: 2021 | 2020

Number of items: 2.

2021

Witkowska McConnell, W. , Davis, C., Sabir, S. R., Garrett, A. , Bradley-Stewart, A., Jajesniak, P., Reboud, J. , Xu, G., Yang, Z. , Gunson, R., Thomson, E. and Cooper, J. (2021) Loop mediated isothermal amplification as a powerful tool for early diagnosis of hepatitis C virus. [Data Collection]

2020

Gilbert, M., Sulikhan, N., Uphyrkina, O., Goncharuk, M., Kerley, L., Hernandez Castro, E., Reeve, R. , Seimon, T., McAloose, D., Seryodkin, I. V., Naidenko, S. V., Davis, C. A., Wilkie, G. S., Vattipally, S. , Adamson, W., Hinds, C., Thomson, E. , Willett, B. , Hosie, M. , Logan, N., McDonald, M. , Ossiboff, R. J., Shevtsova, E. I., Belyakin, S., Yurlova, A. A., Osofsky, S. A., Miquelle, D. G., Matthews, L. and Cleaveland, S. (2020) Distemper, extinction and vaccination of the Amur tiger. [Data Collection]

This list was generated on Thu Apr 18 09:03:54 2024 BST.

Visit the Thomson Group webpage

We use cookies

Necessary cookies

Analytics cookies

Hotjar and Clarity

Professor Emma Thomson

Research interests

Publications

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2011

2010

2009

2008

2007

2006

2004

2003

Articles

Grants

Supervision

Research datasets

2021

2020